Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of PCSK9 Inhibitor on Retinal Microvessels in Patients With Coronary Heart Disease After Intensive Lipid-lowering Therapy

NCT05802108 is registered in ClinicalTrials.gov with Zibo Central Hospital as lead sponsor.

NCT NCT05802108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05802108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of PCSK9 Inhibitor on Retinal Microvessels in Patients With Coronary Heart Disease After Intensive Lipid-lowering Therapy
Lead sponsor
Zibo Central Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
July 1, 2022
Completion date
June 30, 2024
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adverse effect of cardiovascular medications (diagnosis)